Page 48 - Royal Devon News Today

TRADING UPDATES: Henry Boot gets planning boost; Beximco sales jump Fri, 30th Apr 2021 14:15 (Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Henry Boot PLC - Sheffield, England-based construction and property development - Says Phoenix 10 development in West Midlands given approval by planning committee. "Given its industrial past, the Walsall scheme requires extensive remediation works ahead of ...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

Card Factory moves higher after physical stores do better than expected A look at Fridays major share movers on the London Stock Exchange Card Factory PLC (LON:CARD) added 7% to 84.3p before close after announcing that performance following the reopening of stores in England and Wales has topped expectations. Sites in Scotland will resume trading on 26 April while those in Northern Ireland have reopened today. The greeting cards retailer has also headline terms for refinancing with its banks, w...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

No Covid patients at three of Devon’s four hospitals, NHS figures reveal And across Devon and Cornwall, there are no patients in mechanical ventilation beds Updated The video will auto-play soon8Cancel Play now Three of Devon’s four hospitals are free of Covid-19 patients, latest figures from the NHS reveal – with no patients across Devon and Cornwall on ventilators. There have been no patients in hospital in North Devon following a positive Covid-19 test for more than three week...

email article In patients with inflammatory bowel disease (IBD), treatment with infliximab (Remicade) was associated with attenuated immunogenicity to a single dose of either the Pfizer or AstraZeneca COVID-19 vaccine, a large British cohort study found. Concurrent use of an immunomodulator with infliximab, a tumor necrosis factor (TNF) inhibitor, further reduced immunogenicity to either vaccine, reported Tariq Ahmad, MD, of the Royal Devon and Exeter National Health Service (NHS) Foundat...

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses. The research measured antibody responses after vaccination with the Pfizer/BioNTech or the Oxford/AstraZeneca COVID-19 vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) bi...

 E-Mail People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses. The research measured antibody responses after vaccination with the Pfizer/BioNTech or the Oxford/AstraZeneca COVID-19 vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) biologic drug, prescribed to around two million people wor...